Mycobacterium tuberculosis is the species of bacteria that is the causative agent of tuberculosis. Those at high risk for tuberculosis include the elderly, infants, and individuals already infected with a disease that affects the immune system. This makes M. tuberculosis a common source of nosocomial infections, and the emergence of drugresistant strains of the bacteria calls for research into new drugs for treatment of infection with M. tuberculosis. One possible method of treatment involves targeting a putative exopolyphosphatase encoded by the gene Mt1054. An Escherichia coli homologue of this protein regulates the levels of polyphosphate and guanosine 5'-triphosphate 3'-diphosphate (pppGpp), both of which act as signaling molecules during amino acid starvation. The presence of the protein encoded by Mt1054 has been shown to affect biofilm formation and sliding motility in Mycobacterium smegmatis. In this research, Mt1054 will be inserted into the expression plasmid pET30. The protein will be expressed and purified, and enzymatic assays will be conducted on the purified protein in order to determine its phosphohydrolytic enzyme activity. This information can be used in the future to develop methods of modulating M. tuberculosis exopolyphosphatase activity. By doing so, clinicians may be able to trick the bacteria out of going into stationary phase and developing biofilms. Disrupting the ability of M. tuberculosis to form biofilms could increase the susceptibility of this bacterium to antibiotics and decrease the mortality rate of this potentially deadly disease. 
